Matches in SemOpenAlex for { <https://semopenalex.org/work/W2145104284> ?p ?o ?g. }
- W2145104284 endingPage "1265" @default.
- W2145104284 startingPage "1261" @default.
- W2145104284 abstract "Abstract Background. No prospective trials have specifically addressed the efficacy and safety of panitumumab in elderly patients with metastatic colorectal cancer (CRC). We aimed at assessing the efficacy and safety of single agent panitumumab in “frail” elderly patients diagnosed with metastatic RAS and BRAF wild-type CRC. Materials and Methods. Forty elderly patients (aged ≥75 years) with metastatic RAS-BRAF wild-type CRC received off-label prescriptions of single-agent panitumumab at seven Italian institutions. Treatment was administered as first line in patients with absolute contraindication to any chemotherapy or as second-line treatment after failure of a fluoropyrimidine-based treatment, in the presence of contraindication to irinotecan. The outcome measures included objective response rate (ORR), as well as progression-free survival (PFS), disease control rate (DCR), overall survival (OS), and safety. Results. The median PFS and OS were 6.4 months (95% confidence interval [CI]: 4.9–8 months) and 14.3 months (95% CI: 10.9–17.7 months), respectively. ORR was 32.5%, and DCR was 72.5%. Dose reductions related to adverse events (AEs) were reported in 9 (23%) patients, but no permanent treatment discontinuation caused by was reported. The most frequent grade 3 AE was skin rash, with an incidence of 20%. Conclusion. Panitumumab is effective and well-tolerated in frail elderly patients with RAS-BRAF wild-type metastatic CRC and deemed unfit for chemotherapy. A randomized study is needed to confirm these data. Implications for Practice: Treatment of elderly patients with metastatic colorectal cancer represents a difficult challenge in clinical practice. A significant proportion of frail elderly patients do not receive treatment, reflecting ongoing uncertainty of clinical benefit and toxicity of chemotherapy. Unfit condition in this cohort of patients further limits antineoplastic prescription and consequently patient survival. RAS and BRAF wild-type status could help select an elderly and unfit population that could benefit from anti-epidermal growth factor receptor single agent therapy. In the present study, single-agent off-label panitumumab was effective and well-tolerated as first-line treatment in frail elderly patients deemed unfit for chemotherapy for metastatic RAS and BRAF wild-type colorectal cancer." @default.
- W2145104284 created "2016-06-24" @default.
- W2145104284 creator A5004635457 @default.
- W2145104284 creator A5013554030 @default.
- W2145104284 creator A5019125073 @default.
- W2145104284 creator A5026460566 @default.
- W2145104284 creator A5028325185 @default.
- W2145104284 creator A5034600064 @default.
- W2145104284 creator A5038576978 @default.
- W2145104284 creator A5041185139 @default.
- W2145104284 creator A5045419569 @default.
- W2145104284 creator A5045768721 @default.
- W2145104284 creator A5051613962 @default.
- W2145104284 creator A5052353123 @default.
- W2145104284 creator A5054413273 @default.
- W2145104284 creator A5064858820 @default.
- W2145104284 creator A5077222725 @default.
- W2145104284 creator A5079437223 @default.
- W2145104284 creator A5080776095 @default.
- W2145104284 creator A5081985776 @default.
- W2145104284 creator A5082796937 @default.
- W2145104284 creator A5085100580 @default.
- W2145104284 creator A5090671983 @default.
- W2145104284 date "2015-10-07" @default.
- W2145104284 modified "2023-10-13" @default.
- W2145104284 title "Single-Agent Panitumumab in Frail Elderly Patients With Advanced <i>RAS</i> and <i>BRAF</i> Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope" @default.
- W2145104284 cites W1832060645 @default.
- W2145104284 cites W1969861347 @default.
- W2145104284 cites W1985199765 @default.
- W2145104284 cites W2005348280 @default.
- W2145104284 cites W2019607817 @default.
- W2145104284 cites W2024761986 @default.
- W2145104284 cites W2028486975 @default.
- W2145104284 cites W2038386885 @default.
- W2145104284 cites W2046021994 @default.
- W2145104284 cites W2048648630 @default.
- W2145104284 cites W2085633477 @default.
- W2145104284 cites W2098354753 @default.
- W2145104284 cites W2106789440 @default.
- W2145104284 cites W2112570485 @default.
- W2145104284 cites W2125942839 @default.
- W2145104284 cites W2130816987 @default.
- W2145104284 cites W2134142320 @default.
- W2145104284 cites W2134519717 @default.
- W2145104284 cites W2142675265 @default.
- W2145104284 cites W2147297736 @default.
- W2145104284 cites W2159296014 @default.
- W2145104284 cites W2168579528 @default.
- W2145104284 cites W2415680948 @default.
- W2145104284 doi "https://doi.org/10.1634/theoncologist.2015-0171" @default.
- W2145104284 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4718427" @default.
- W2145104284 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26446234" @default.
- W2145104284 hasPublicationYear "2015" @default.
- W2145104284 type Work @default.
- W2145104284 sameAs 2145104284 @default.
- W2145104284 citedByCount "37" @default.
- W2145104284 countsByYear W21451042842016 @default.
- W2145104284 countsByYear W21451042842017 @default.
- W2145104284 countsByYear W21451042842018 @default.
- W2145104284 countsByYear W21451042842019 @default.
- W2145104284 countsByYear W21451042842020 @default.
- W2145104284 countsByYear W21451042842021 @default.
- W2145104284 countsByYear W21451042842022 @default.
- W2145104284 countsByYear W21451042842023 @default.
- W2145104284 crossrefType "journal-article" @default.
- W2145104284 hasAuthorship W2145104284A5004635457 @default.
- W2145104284 hasAuthorship W2145104284A5013554030 @default.
- W2145104284 hasAuthorship W2145104284A5019125073 @default.
- W2145104284 hasAuthorship W2145104284A5026460566 @default.
- W2145104284 hasAuthorship W2145104284A5028325185 @default.
- W2145104284 hasAuthorship W2145104284A5034600064 @default.
- W2145104284 hasAuthorship W2145104284A5038576978 @default.
- W2145104284 hasAuthorship W2145104284A5041185139 @default.
- W2145104284 hasAuthorship W2145104284A5045419569 @default.
- W2145104284 hasAuthorship W2145104284A5045768721 @default.
- W2145104284 hasAuthorship W2145104284A5051613962 @default.
- W2145104284 hasAuthorship W2145104284A5052353123 @default.
- W2145104284 hasAuthorship W2145104284A5054413273 @default.
- W2145104284 hasAuthorship W2145104284A5064858820 @default.
- W2145104284 hasAuthorship W2145104284A5077222725 @default.
- W2145104284 hasAuthorship W2145104284A5079437223 @default.
- W2145104284 hasAuthorship W2145104284A5080776095 @default.
- W2145104284 hasAuthorship W2145104284A5081985776 @default.
- W2145104284 hasAuthorship W2145104284A5082796937 @default.
- W2145104284 hasAuthorship W2145104284A5085100580 @default.
- W2145104284 hasAuthorship W2145104284A5090671983 @default.
- W2145104284 hasBestOaLocation W21451042841 @default.
- W2145104284 hasConcept C121608353 @default.
- W2145104284 hasConcept C126322002 @default.
- W2145104284 hasConcept C142724271 @default.
- W2145104284 hasConcept C143998085 @default.
- W2145104284 hasConcept C197934379 @default.
- W2145104284 hasConcept C204787440 @default.
- W2145104284 hasConcept C207103383 @default.
- W2145104284 hasConcept C2776494729 @default.
- W2145104284 hasConcept C2778332735 @default.
- W2145104284 hasConcept C2778375690 @default.
- W2145104284 hasConcept C2778570526 @default.